open access

Vol 80, No 3 (2022)
Original article
Published online: 2022-02-03
Get Citation

Very long-term follow-up of patients with coronary bifurcation lesions treated with bioresorbable scaffolds

Sylwia Iwańczyk1, Aleksander Araszkiewicz1, Marek Grygier1, Aneta Klotzka1, Małgorzata Pyda1, Włodzimierz Skorupski1, Przemysław Mitkowski1, Magdalena Łanocha1, Stefan Grajek1, Andrzej Drewnicki1, Tatiana Mularek-Kubzdela1, Maciej Lesiak1
DOI: 10.33963/KP.a2022.0031
·
Pubmed: 35040483
·
Kardiol Pol 2022;80(3):307-314.
Affiliations
  1. 1st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland

open access

Vol 80, No 3 (2022)
Original article
Published online: 2022-02-03

Abstract

Backgrounds: The data concerning the use of bioresorbable vascular scaffolds (BVS) in coronary bifurcation lesions are limited.
Aims: The objective of the study was to evaluate the early and very long-term clinical outcomes of bifurcation stenting with ABSORB BVS.
Methods: One hundred consecutive patients with coronary bifurcation lesions treated with BVS were included. A total of 124 BVS were implanted. Provisional side branch stenting was performed in 66 patients, distal main stenting in 14 patients, systematic T stenting in 2, and T with minimal protrusion (TAP) in 5 patients. Side branch ostial stenting was performed in additional 12 patients.
Results: The procedural success was achieved in 98% of patients. In long-term follow-up, the rate of cardiac death was 4.0%, target vessel myocardial infarction was 5.0%, and target vessel revascularization (TVR) was 11%. The cumulative incidence of definite/probable scaffold thrombosis (ST) was 2% at long-term follow-up. Comparison with the historical drug-eluting stents (DES) group revealed higher mortality and major adverse cardiac events rate in the ABSORB group.
Conclusions: Stenting of coronary bifurcation lesions of low-to-moderate complexity with BVS was feasible with good acute performance and acceptable results. However, the risk of death and major adverse cardiovascular events was higher as compared with DES.

Abstract

Backgrounds: The data concerning the use of bioresorbable vascular scaffolds (BVS) in coronary bifurcation lesions are limited.
Aims: The objective of the study was to evaluate the early and very long-term clinical outcomes of bifurcation stenting with ABSORB BVS.
Methods: One hundred consecutive patients with coronary bifurcation lesions treated with BVS were included. A total of 124 BVS were implanted. Provisional side branch stenting was performed in 66 patients, distal main stenting in 14 patients, systematic T stenting in 2, and T with minimal protrusion (TAP) in 5 patients. Side branch ostial stenting was performed in additional 12 patients.
Results: The procedural success was achieved in 98% of patients. In long-term follow-up, the rate of cardiac death was 4.0%, target vessel myocardial infarction was 5.0%, and target vessel revascularization (TVR) was 11%. The cumulative incidence of definite/probable scaffold thrombosis (ST) was 2% at long-term follow-up. Comparison with the historical drug-eluting stents (DES) group revealed higher mortality and major adverse cardiac events rate in the ABSORB group.
Conclusions: Stenting of coronary bifurcation lesions of low-to-moderate complexity with BVS was feasible with good acute performance and acceptable results. However, the risk of death and major adverse cardiovascular events was higher as compared with DES.

Get Citation

Keywords

bifurcation lesion, bioresorbable scaffolds, percutaneous coronary interventio

Supp./Additional Files (1)
Supplementary material
Download
599KB
About this article
Title

Very long-term follow-up of patients with coronary bifurcation lesions treated with bioresorbable scaffolds

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 80, No 3 (2022)

Article type

Original article

Pages

307-314

Published online

2022-02-03

Page views

2148

Article views/downloads

226

DOI

10.33963/KP.a2022.0031

Pubmed

35040483

Bibliographic record

Kardiol Pol 2022;80(3):307-314.

Keywords

bifurcation lesion
bioresorbable scaffolds
percutaneous coronary interventio

Authors

Sylwia Iwańczyk
Aleksander Araszkiewicz
Marek Grygier
Aneta Klotzka
Małgorzata Pyda
Włodzimierz Skorupski
Przemysław Mitkowski
Magdalena Łanocha
Stefan Grajek
Andrzej Drewnicki
Tatiana Mularek-Kubzdela
Maciej Lesiak

References (30)
  1. Pan M, Suárez de Lezo J, Medina A, et al. Simple and complex stent strategies for bifurcated coronary arterial stenosis involving the side branch origin. Am J Cardiol. 1999; 83(9): 1320–1325.
  2. Lefèvre T, Louvard Y, Morice MC, et al. Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv. 2000; 49(3): 274–283, doi: 10.1002/(sici)1522-726x(200003)49:3<274::aid-ccd11>3.0.co;2-n.
  3. Al Suwaidi J, Berger PB, Rihal CS, et al. Immediate and long-term outcome of intracoronary stent implantation for true bifurcation lesions. J Am Coll Cardiol. 2000; 35(4): 929–936.
  4. Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004; 109(10): 1244–1249.
  5. Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation. 2010; 121(10): 1235–1243.
  6. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17): 2126–2130.
  7. Hoye A, Ong ATL, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol. 2005; 45(6): 947–953.
  8. Colombo A, Bramucci E, Saccà S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation. 2009; 119(1): 71–78.
  9. Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007; 115(8): 1051–1058.
  10. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011; 57(11): 1314–1322.
  11. Brugaletta S, Heo JHo, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J. 2012; 33(11): 1325–1333.
  12. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014; 9(11): 1271–1284.
  13. Louvard Y, Medina A, Stankovic G. Definition and classification of bifurcation lesions and treatments. EuroIntervention. 2010; 6 Suppl J: J31–J35.
  14. Medina A, Lezo JS, Pan M. A New Classification of Coronary Bifurcation Lesions. Rev Esp Cardiol. 2006; 59(2): 183.
  15. Drewnicki A. Early and long–term evaluation of the results of implantation of a new generation of antiproliferative drug–eluting stents. Dissertation. 1st Department of Cardiology, Chair of Cardiology, Poznan University of Medical Sciences, Poznań 2018.
  16. Otsuka F, Pacheco E, Perkins LEL, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014; 7(3): 330–342.
  17. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17): 2344–2351.
  18. White HD, Thygesen K, Alpert JS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012; 33(20): 2551–2567.
  19. Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation. 2010; 121(10): 1235–1243.
  20. Chen SL, Santoso T, Zhang JJ, et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. J Am Coll Cardiol. 2011; 57(8): 914–920.
  21. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10(10): 1144–1153.
  22. Tamburino C, Latib A, van Geuns RJ, et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015; 11(1): 45–52.
  23. Tamburino C, Latib A, van Geuns RJ, et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015; 11(1): 45–52.
  24. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011; 123(13): 1400–1409.
  25. Łanocha M, Lesiak M. Complete healing of a bifurcation lesion treated with the implantation of 2 bioresorbable vascular scaffolds with the T and small protrusion technique. Kardiol Pol. 2019; 77(4): 488–489.
  26. Lesiak M, Łanocha M, Araszkiewicz A, et al. Percutaneous coronary intervention for chronic total occlusion of the coronary artery with the implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry. EuroIntervention. 2016; 12(2): e144–e151.
  27. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016; 388(10059): 2479–2491.
  28. Kereiakes DJ, Ellis SG, Metzger DC, et al. ABSORB III Investigators, ABSORB III Investigators. 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. J Am Coll Cardiol. 2017; 70(23): 2852–2862.
  29. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group, ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
  30. Włodarczak A, Łanocha M, Lesiak M, et al. Long-term clinical follow-up of the resorbable magnesium scaffolds in acute coronary syndrome patients. Kardiol Pol. 2021; 79(7-8): 827–832.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl